Experienced in Factor 7 Deficiency

Heidi Glosli

Oslo, NO 
Experienced in Factor 7 Deficiency
Oslo, NO 
OverviewLocationsClinical Research

Overview

Heidi Glosli practices in Oslo, Norway. Ms. Glosli is rated as an Experienced expert by MediFind in the treatment of Factor 7 Deficiency. Her top areas of expertise are Rhabdomyosarcoma, Hemophilia A, Blood Clots, and Adult Soft Tissue Sarcoma.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Factor 7 Deficiency.

Gender
Female

Locations

Oslo, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ≥ 6 Months to < 18 Years Receiving Treatment With Opioids
A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ≥ 6 Months to < 18 Years Receiving Treatment With Opioids
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

43 Total Publications

Characterization of a novel factor X variant, p.F139L, associated with bleedings in heterozygous and compound heterozygous form.
Characterization of a novel factor X variant, p.F139L, associated with bleedings in heterozygous and compound heterozygous form.
Journal: Thrombosis research
Published: May 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Glosli's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile